1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

BACKGROUND: Black Americans are disproportionately impacted by HIV. The BRAAVE 2020 study, evaluated the safety and efficacy of switching to the guidelines-recommended single-tablet regimen bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) in Black adults through week (W) 48. METHODS: Adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagins, Debbie, Kumar, Princy, Saag, Michael, Wurapa, Anson K, Brar, Indira, Berger, Daniel, Osiyemi, Olayemi, Hileman, Corrilynn, Ramgopal, Moti, McDonald, Cheryl, Blair, Christiana, Andreatta, Kristen, Collins, Sean E, Brainard, Diana M, Martin, Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776728/
http://dx.doi.org/10.1093/ofid/ofaa439.1232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776728/
http://dx.doi.org/10.1093/ofid/ofaa439.1232

Ejemplares similares